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Paracoccidioidomycosis is a fungal disease endemic in Latin America. Polyclonal
antibodies to acidic glycosphingolipids (GSLs) from Paracoccidioides brasiliensis
opsonized yeast forms in vitro increasing phagocytosis and reduced the fungal burden
of infected animals. Antibodies to GSL were active in both prophylactic and therapeutic
protocols using a murine intratracheal infection model. Pathological examination of the
lungs of animals treated with antibodies to GSL showed well-organized granulomas and
minimally damaged parenchyma compared to the untreated control. Murine peritoneal
macrophages activated by IFN-γ and incubated with antibodies against acidic GSLs
more effectively phagocytosed and killed P. brasiliensis yeast cells as well as produced
more nitric oxide compared to controls. The present work discloses a novel target of
protective antibodies against P. brasiliensis adding to other well-studied mediators of
the immune response to this fungus.
Keywords: Paracoccidioides brasiliensis, paracoccidioidomycosis, glycosphingolipids, polyclonal antibodies,
nitric oxide
INTRODUCTION
The agents of Paracoccidioidomycosis (PCM) are a complex group of fungi within the
Paracoccidioides genus comprised of four distinct phylogenetic lineages known as PS2, PS3, S1,
and Pb01-like (Matute et al., 2006; Teixeira et al., 2009). PCM is a systemic granulomatous
disease initiated by the inhalation of Paracoccidioides sp. conidia that subsequently transform into
yeast forms in the lungs. Paracoccidioides sp. grows in the yeast form at human physiological
temperature and in the mycelial form at 25◦C (Franco et al., 1993). PCM is endemic in a broad
region fromMexico to Argentina, although∼80% of diagnosed patients are in Brazil. Most patients
are rural workers but cases also occur in urban centers, especially those located along routes used
by migrant workers (Restrepo, 1985; McEwen et al., 1995). Among the fungal diseases, PCM is the
prevalent systemic mycosis in Latin America, with the highest mortality rate among the systemic
mycoses in Brazil (Prado et al., 2009).
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Previous studies have identiﬁed diﬀerent glucans related to
dimorphism in Paracoccidioides brasiliensis (Kanetsuna and
Carbonell, 1970; Kanetsuna et al., 1972), antigenic glycoproteins
including the major diagnostic antigen gp43 (Puccia et al.,
1986), galactomannans (San-Blas et al., 2005), brassicasterol,
phospholipids (Pereira et al., 2010; Longo et al., 2013), and
glycolipids (Puccia et al., 2011). Glycosphingolipids (GSLs)
are important molecules in fungi, involved in adhesion,
cell recognition, cell diﬀerentiation, signal transduction, and
regulation of cell proliferation (Barreto-Bergter et al., 2004,
2011; Nimrichter et al., 2005; Bertini et al., 2007). GSLs from
Saccharomyces cerevisiae and other species are structurally
diﬀerent from those of mammals mainly due to the presence of
inositolphosphoceramide (IPC) as the core structure (Dickson
and Lester, 2002). Acidic and neutral GSLs have both been
identiﬁed in yeast and mycelium forms of P. brasiliensis (Toledo
et al., 1995).
Bertini et al. (2007) used 31 sera from PCM patients to
determine their reactivity to acidic GSLs Pb-1 and Pb-2 by
ELISA. Only the Pb-1 antigen, which has a Galf residue,
was reactive with the PCM patients’ sera. Pb-2, which lacks
the Galf residue, was not recognized. The titer of antibodies
to Pb-1 increased after the start of antifungal treatment and
decreased after 5 months of treatment; thus, the Pb-1 ELISA is
a potentially clinically useful test to evaluate patient response
to therapy. The authors also investigated the role of GSLs
in the diﬀerentiation and colony formation of P. brasiliensis,
Histoplasma capsulatum, and Sporothrix schenckii using three
monoclonal antibodies (mAbs) against fungal GSLs: mAbMEST-
1 directed to residues of β-D-galactofuranose linked to mannose,
mAb MEST-2 directed to glucosylceramide, and mAb MEST-
3 directed to Pb-2. These mAbs exerted a strong inhibitory
activity on growth, diﬀerentiation and colony formation of these
fungi. Experiments, however, using mAb MEST-2, showed no
signiﬁcant inhibition of CFUs or eﬀect in the fungal dimorphism
(Toledo et al., 2010). On the other hand, addition of puriﬁed
human antibodies, directed to GlcCer, inhibited cell budding and
growth of Cryptococcus neoformans (Rodrigues et al., 2000).
Therapeutic vaccination with fungal antigens or passive
transfer of antibodies can boost the cell immune response
and add to the protective eﬀect of chemotherapy, eventually
counteracting a relapsing disease and reducing ﬁbrotic sequels.
Both the innate immune response and the adaptive immunity
are important for the antifungal protective eﬀect (Travassos and
Taborda, 2012).
The ﬁrst evidence of antibody-mediated protection against
P. brasiliensis was shown with the passive transfer of two murine
mAbs against a glycoprotein of 70 kD which is recognized by
96% of sera from PCM patients (de Mattos Grosso et al., 2003).
Administration of these mAbs led to a signiﬁcant reduction in
the CFUs and the number and size of granulomas in the lungs of
experimentally infected mice. Studies on the eﬀect of mAbs to the
major diagnostic antigen gp43 provide additional insights into
the role of antibody protection in PCM (Travassos and Taborda,
2012).
Given the potential role of GSLs in the virulence of
P. brasiliensis, we investigated the eﬀect of anti-acidic
GSLs polyclonal antibodies on the infection clearance,
using experimental prophylactic and therapeutic models
and, we have found that at least to polyclonal antibodies
to GSL in both models studied are protective to PCM
experimental.
MATERIALS AND METHODS
Fungal Strain
Virulent P. brasiliensis Pb18 yeast cells were maintained by
weekly passages on solid Sabouraud medium (Gibco) at 37◦C
and were used after 7–10 days of growth. Before experimental
infection, the cultures were grown in Sabouraud Broth at 37◦C
for 5 days (Buissa-Filho et al., 2008). The fungal cells were washed
in phosphate-buﬀered saline (PBS; pH 7.2) and counted in a
hemocytometer. The viability of fungal suspensions was assessed
by 0.4% Trypan Blue (Sigma) exclusion staining and was always
higher than 90% (Taborda et al., 1998).
Extraction of GSLs
Crude lipid mixtures were extracted from P. brasiliensis yeast
cells by homogenization using a mixer, three times with 200 mL
of 2-propanol/hexane/water (IHW, 55:20:25, v/v/v, upper phase
discarded), and twice with 200 mL of chloroform/methanol
(CM, 2:1, v/v). The ﬁve extracts were pooled, dried on a
rotary evaporator, dialyzed against distilled water, lyophilized,
suspended in chloroform/methanol/water (30:60:8, v/v/v). Acidic
glycolipids from the crude lipid extract were puriﬁed by
ion exchange chromatography on DEAE-Sephadex A-25 (GE-
Healthcare). The elution of the samples was performed following
protocols I and II. In protocol I, GSLs were eluted from DEAE-
Sephadex A-25 with ﬁve volumes of the following solvents (Carlo
Erba): (a) CHCl3:CH3OH:H2O (30:60:8, v/v/v); (b) CH3OH;
(c) Sodium acetate 0.2% in methanol; (d) sodium acetate 0.6%
in methanol. Fractions corresponding to the neutral glycolipids
were eluted in the ﬁrst solvent and the acidic fraction was eluted
with the third solvent. In protocol II, the fraction of acidic
glycolipids was puriﬁed by column chromatography on Silica
Gel 60 (Merck) using ﬁve solvents: (a) CHCl3:CH3OH (8:2, v/v);
(b) CHCl3:CH3OH (6:4, v/v); (c) CHCl3:CH3OH (4:6, v/v); (d)
CHCl3:CH3OH (2:8, v/v), and (e) CH3CHOHCH3:C6H14:H2O
(55:20:25, v/v/v). The purity was checked by high resolution
thin layer chromatography (HPTLC; Merck) developed in the
solvent CHCl3:CH3OH:CaCl2 0.02% at 60:40:9 (v/v/v). HPTLC
plates were sprayed with 90% acetone in primuline (Sigma) and
visualized under ultraviolet light. Compounds were revealed with
0.5% orcinol (Sigma), in 3 M sulfuric acid (H2SO4; Straus et al.,
1993).
Animal Use and Ethics Statement
BALB/c, 6 to 8-week-old male,mice were bred at the University of
São Paulo animal facility under speciﬁc pathogen-free conditions.
All animals were handled in accordance with good animal
practice as deﬁned by the rules of the national animal welfare
bodies. The Animal Care and Use Committee of the University
of São Paulo approved all in vivo testing.
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Polyclonal Antibodies to GSL
Polyclonal antibodies were raised in BALB/c mice by four
immunizations with 50μg of puriﬁed GSLs in Incomplete Freund
Adjuvant, intraperitoneally. The animals were bled 24 h before
the immunizations, to collect the pre-immune serum. ELISA was
used to analyze the immune sera. Polyclonal antibodies obtained
from the animals were puriﬁed by aﬃnity chromatography using
a protein-A column, according to the manufacturer’s direction
(Thermo Scientiﬁc, Netherlands). Protein-A tightly binds IgG2a,
IgG2b, and IgG3, while it binds weakly to IgG1 and does not bind
IgM. The polyclonal antibodies were dialyzed and concentrated
by AMICON system with total concentration being determined
by Nanodrop 1000. ELISA was also used to titer anti-GSL
antibodies. The control polyclonal serum was generated in the
same manner, except that bovine serum albumin (BSA-Sigma)
was used as the immunogen.
Intratracheal Infection of BALB/c Mice
BALB/c mice were inoculated intratracheally (i.t.) with virulent
P. brasiliensis Pb18. Mice were anesthetized intraperitoneally
(i.p.) with 200μl of a solution containing 80 mg/kg ketamine and
10 mg/kg of xylazine (União Química Farmacêutica, Brazil). For
inoculation, the mouse’s neck was hyperextended, the trachea was
exposed at the level of the thyroid, and 3 × 105 yeast cells in PBS
were injected i.t. using a 26-gage needle. Incisions were sutured
with 5-0 silk.
Protective Effects of Polyclonal
Antibodies to Acidic GSL
We studied two protocols: prophylactic and therapeutic. In the
prophylactic protocol, mice were treated with 1 mg antibodies
to GSL i.p. and then infected 24 h later with P. brasiliensis.
These mice were euthanized 15 and 30 days after infection. For
therapeutic protocols, animals were ﬁrst infected i.t. and then
immunized i.p. 30 days later with 1 mg of polyclonal antibodies
to GSL. These mice were euthanized at either 45 or 60 days
after intratracheal infection. In both therapeutic and prophylactic
protocols, experimental groups included mice that received 1 mg
of antibodies to BSA as a control for the polyclonal antibodies.
Fungal Burden in Organs of Infected
Mice
Fungal burdens were determined by CFUs counting.
Sections of lungs were removed, weighed, and homogenized
in 1ml of PBS. Samples (100 μl) were plated on solid
brain heart infusion (BHI) medium supplemented with
4% fetal calf serum (Vitrocell, Brazil), 5% P. brasiliensis
(strain 192)-spent culture medium, and 100 IU/ml
streptomycin-penicillin (Sigma–Aldrich, USA). Petri dishes
were incubated at 37◦C and colonies were counted after
7 days.
Histopathology
Sections of murine lungs were ﬁxed in 10% buﬀered formalin and
embedded in paraﬃn for sectioning. The sections were stained by
the Gomori-Grocott method for fungal cells detection and were
examined microscopically.
Cytokine Detection
Sections of excised lungs were homogenized in 2 ml of PBS in the
presence of protease inhibitors: benzamidine HCl (4 mM), EDTA
disodium salt (1 mM), N-ethylmaleimide (1 mM), and pepstatin
(1.5 mM) (Sigma). The supernatants were assayed for IL-4, IL-10,
IL-12, TNF-α, and IFN-γ using enzyme-linked immunosorbent
assay (ELISA) kits (BD OpTeia, San Diego, CA, USA). The
detection limits of the assays were as follows: 7.8 pg/ml for IL-
4; 31.25 pg/ml for IL-10, 62.5 pg/ml for IL-12, 15.6 pg/ml for
TNF-α, and 7.8 pg/ml for IFN-γ, as previously determined by the
manufacturer.
Phagocytosis Assay
In vitro phagocytosis experiments were carried out with the
J774.16 macrophage-like cell line. In vitro phagocytosis was
performed according to our established protocol (Taborda and
Casadevall, 2001, 2002) with minor modiﬁcation. Cells were
plated in 96-well tissue culture plates (TPP, Switzerland) at
a density of 105 cells per well, stimulated with 50 U/ml
recombinant murine IFN-γ (BdBiosciences, USA) and incubated
at 37◦C overnight. The medium in each well was then replaced
with the following additions: (1) acidic glycolipids puriﬁed, at 100
and 200 μg/ml; (2) antibodies from mouse serum immunized
with GSL, puriﬁed by Protein A; (3) polyclonal antibodies to
GSL puriﬁed by Protein A, at 100 μg/ml, with the concentration
determined by ELISA; (4) polyclonal antibodies to BSA, at
100 μg/ml. P. brasiliensis cells were added at a ratio of 5:1
macrophages/yeast cells and then incubated at 37◦C for 6, 12,
and 24 h. The wells were then washed several times with sterile
PBS, ﬁxed with cold absolute methanol, and stained with a 1/20
solution of Giemsa (Sigma–Aldrich, USA). Phagocytosed yeasts
were counted by light microscopy at 400× magniﬁcation. The
phagocytic index (PI) is deﬁned as PI = P × F, where P is the
percentage of macrophages with internalized yeasts and F is the
average number of yeast cells per macrophage. Experiments were
carried out in triplicate and ﬁve to eight diﬀerent ﬁelds were
counted.
Antifungal Activity of Macrophages
After incubation of the macrophages, the viability of the
P. brasiliensis yeast cells was determined by plating supernatants
on BHI agar supplemented with 4% FCS and 5% spent culture
medium of P. brasiliensis strain192. CFUs were counted after
7 days of incubation at 37◦C.
Production of Nitric Oxide
The levels of nitric oxide metabolite (nitrite) in the culture
supernatant of macrophages challenged with opsonized yeasts
were determined by Griess reaction (Pick and Keisari, 1981). All
determinations were performed in triplicate.
Statistical Analysis
Results were analyzed using GraphPad 5.0 software (GraphPad
Inc., San Diego, CA, USA). Statistical comparisons were made
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by analysis of variance (one-way ANOVA) followed by Turkey–
Kramer posttest and student’s t-test. All values were reported as
means ± standard errors of the mean (SEM). P-values of <0.05
indicated statistical signiﬁcance.
RESULTS
Extraction of GSLs
To purify the GSLs, the crude lipid extract was subjected to ion
exchange chromatography on DEAE-Sephadex A-25 (protocol
I) and A-25 and sequentially in Silica gel 60 (protocol II).
The purity was checked by high-resolution chromatography
(HPTLC); representative gels of extracted GSLs by protocol I and
II are shown in Figure 1. For comparison of chromatographic
mobility, in the protocol I we used a neutral glycolipid (CMH)
standard whereas protocol II used CMH as well as acidic GSL
standards.
Phagocytosis Assay
The capacity of J774.16 macrophage-like cells for the
phagocytosis of P. brasiliensis yeast was assessed using diﬀerent
conditions in 6, 12, and 24 h co-cultures with macrophages
activated by IFN-γ 24 h before the assays. At all time intervals
FIGURE 1 | High resolution thin layer chromatography (HPTLC) of
acidic GSLs purified from the crude lipid extract of Paracoccidioides
brasiliensis. The solvents used were CHCl3:CH3OH:CaCl2 0.02% in the
proportions 60:40:9 (v/v/v). Revelation with 0.5% orcinol in 3 M sulfuric acid
(H2SO4). (A) - (1) Standard CMH, (2) purified acidic GSL (3) purified acidic
GSL. (B) - (1) Standard CMH, (2) purified acidic GSL Standard Acidic, (3)
purified acidic GSL (B). The glycolipids purple stained.
assessed, incubation in the presence of total serum with
polyclonal antibodies against acidic GSL (100 μg/ml) along
with the other antibodies present in total serum, signiﬁcantly
enhanced yeast cell uptake by J774.16 (p = 0.009), when
compared to control groups, cells that received polyclonal
antibodies to BSA at 100 μg/ml or only the acidic glycolipids at
100 and 200 μg/ml (Figure 2A). It is noteworthy that the total
serum contains various kinds of antibodies, not only against
GSL, and that these antibodies might induce macrophage-like
phagocytosis of P. brasiliensis yeasts. However, as can be seen in
Figure 2A, only the puriﬁed GSL antibodies, at all studied times,
signiﬁcantly increased the phagocytosis index, suggesting that
only the polyclonal antibody against GSL has the ability to induce
phagocytosis in this cell line. The speciﬁcity of the polyclonal
antibodies was tested by adding glycolipids during phagocytosis,
which resulted in a partial inhibition of the process (data not
shown).
Antifungal Activity of Macrophages
The fungicidal eﬀects of J774.16 cells on P. brasiliensis was
determined in co-cultures using diﬀerent experimental media.
The macrophage-like cells were lysed and the lysates plated
onto agar; CFUs were counted after 7 days of incubation at
37◦C. It may be observed in Figure 2B that the addition of
polyclonal antibodies and total serum reduced the viability of
the yeast P. brasiliensis internalized by the macrophage-like cells,
as compared to the control groups. Therefore the polyclonal
antibodies to GSL eﬀectively killed P. brasiliensis.
Production of Nitric Oxide
Nitrite levels were detected in culture supernatants of
macrophage-yeast co-cultures using a Griess assay. The levels of
nitric oxide are intrinsically related to the phagocytosis index.
As shown in Figure 2C increased nitric oxide was produced
in macrophage-like cells incubated with total immune serum
and with puriﬁed anti-acidic GSL polyclonal antibodies at all
incubation times (6, 12, and 24 h), as compared to the control
groups. These data are compatible with the results obtained in
the phagocytosis and killing assays.
Fungal Burden in Organs of Infected
Mice
Both treatment approaches reduced the fungal burden in
animal groups that received polyclonal antibodies against acidic
GSL when compared to control groups receiving polyclonal
antibodies against BSA. The prophylactic group, immunized
24 h before infection and examined 15 and 30 days afterwards,
showed a signiﬁcant reduction in the fungal burden evaluated
by CFUs, p = 0.0001 (15 days) and p = 0.0129 (30 days),
as shown in Figure 3A. Moreover the histopathological
analyses showed only a few yeasts in the lungs (Figure 3B.
Slide B2).
In the therapeutic groups, examined 45 and 60 days after
infection with P. brasiliensis and with established disease in the
animals, CFUs decreased in the lungs, p = 0.0001 (45 days) and
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FIGURE 2 | Experiments in vitro: (A) Phagocytosis of yeast cells by J774.16 cells in the presence of polyclonal antibodies to acidic GSL, polyclonal
antibodies to BSA (control), total serum with different polyclonal antibodies and purified acidic GSLs, 100 and 200 µg. Each bar represents the average
of three measurements. Experiments were done in triplicate, and different fields were counted. Significant difference (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.0001).
(B) Killing assay using peritoneal macrophages in the phagocytosis assay. Polyclonal antibodies against BSA (control), purified acidic GSL, total serum with different
polyclonal antibodies, polyclonal anti-acidic GSL antibody. The columns represent the mean average of three readings. Significant values compared to controls,
∗∗∗p < 0.0001, ∗∗p < 0.01. (C) Nitric oxide formed in J774.16 cells cultured with P. brasiliensis yeasts. Polyclonal antibodies to acidic GSL, polyclonal antibodies to
BSA (control), total serum with different polyclonal antibodies, purified acidic GSLs. Nitrite was determined by Griess reagent. Significant difference (∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.0001). #p < 0.05 (student’s t-test).
p = 0.006 (60 days) according to Figure 4A. No yeasts were
detected in the liver and spleen (data not shown).
Histopathological Analyses
At day 15 after infection, the lungs of the control animals
pre-treated with polyclonal antibodies to BSA showed intense
inﬁltrations of inﬂammatory cells with numerous foci of
proliferating fungal cells (Figure 3B. Slide A1). In contrast, the
mice treated with polyclonal antibodies to acidic GSLs displayed
signiﬁcantly less lung tissue inﬁltration, few intact yeast cells,
and large areas with preserved architecture (Figure 3B. Slide
A2). After 30 days, the lungs of animals treated with polyclonal
antibody to BSA showed compact and loose granulomas with
many yeast in the lung tissue (Figure 3B. Slide B1). Although it
is possible to observe yeasts inside lung granulomas, in animals
of the prophylactic group after 30 days, the CFUs did not
account for many yeasts, thereby suggesting that they were
not viable (Figure 3B. Slide B2). The therapeutic protocol also
resulted in enhanced protection against tissue damage induced
by P. brasiliensis. Beneﬁcial results were observed 45 days after
infection in the treated group (Figure 4B. Slide A2) when
compared to the control mice (BSA; Figure 4B. Slide A1). As
shown in Figure 4B. Slides B1 and B2, 60 days after infection,
in both protocols, there was reduced fungal burden in the
lung tissue. Lung architecture remained largely preserved, well-
organized granulomas and a little damage to the lung tissue of
mice treated with anti-GSL polyclonal antibodies. The group that
received polyclonal antibodies to BSA, however, showed loose
granulomas and damage to the lung tissue.
Cytokine Detection
Cytokine levels were measured in the lung tissues of i.t. infected
mice treated with polyclonal antibodies against either BSA or
acidic GSLs. As shown in Figure 5 (prophylactic group) and
Figure 6 (therapeutic group), in the former, animals immunized
with polyclonal antibodies against acidic GSL had higher levels
of IFN-γ after 15 days (p = 0.0328) of infection compared with
mice receiving polyclonal antibodies against BSA. There were no
signiﬁcant diﬀerences in the levels of IL-4 and TNF-α. However,
IL-10 was statistically diﬀerent between the groups (p = 0.0027).
In the therapeutic protocol, animals immunized with
polyclonal antibodies against acidic GSL, showed signiﬁcantly
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FIGURE 3 | (A) Colony forming units (CFU) in the lungs from BALB/c mice
that received 1 mg of polyclonal antibodies against acidic glycolipids and
1 mg anti-BSA polyclonal antibodies (control) 24 h before infection with Pb18
and sacrificed after 15 and 30 days (prophylactic protocol). Significant values
comparing the lungs of treated and control groups. ∗p < 0.05, ∗∗p < 0.01.
(B) Representative lung sections: Prophylactic protocol. 24 h prior to infection,
mice received polyclonal antibodies to acidic GSLs. Histopathological
sections of murine lungs 15 (A1, A2) and 30 (B1, B2) days after i.t. infection.
(A1, B1) Lungs from control mice; (A2, B2) Histopathological sections after i.t.
infection. Photographs of sections were taken at 100× magnification.
higher levels of IFN-γ (p = 0.0083) in animals sacriﬁced after
60 days of infection with P. brasiliensis and of IL-12 (p = 0.0085)
after 45 and 60 days of infection.
DISCUSSION
Studies on antibody immunity against fungal pathogens have
revealed that experiments with polyclonal sera may not
conclusively validate or disprove the capacity of antibody
to eﬀectively modify disease pathogenesis. This quandary
arises due to the fact that polyclonal serum may consist
of a mixture of protective, irrelevant, or even detrimental
antibodies, and the relative quantity of each can dictate whether
or not a protective eﬀect is measured (Casadevall, 1995).
The polyclonal antibodies also diﬀer in isotype quantity and
speciﬁcity, which further complicates the assessment of eﬃcacy.
Batista et al. (2014) showed that GSLs from P. brasiliensis
FIGURE 4 | (A) Colony forming units (CFU) in the lungs from BALB/c mice
that received 1 mg of polyclonal antibodies against acidic glycolipids and
1 mg anti- BSA polyclonal antibodies (control) 30 days after infection with
Pb18 and sacrificed after 45 and 60 days (therapeutic protocol). Significant
values comparing the lungs of treated and control groups. ∗∗p < 0.01,
∗∗∗p < 0.0001. (B) Representative lung sections: therapeutic protocol. 3 days
after i.t. infection, mice received polyclonal antibodies to acidic GSLs. Controls
received polyclonal antibodies to BSA. Representative histopathological
sections 45 days after i.t. infection: (A1) Lung from control mouse; (A2) Lung
from treated mouse. After 60 days of i.t. infection: (B1) Control; (B2) Treated.
Photographs of sections were taken at 100× magnification.
aﬀected the function of human monocytes and dendritic
cells, interfering with antigen presentation. Toledo et al.
(2010) demonstrated that mAbs against the P. brasiliensis
glycolipid antigen, had a strong inhibitory activity in vitro
on diﬀerentiation and colony formation of P. brasiliensis,
H. capsulatum, and S. schenckii. Regardless, on the present
work, the polyclonal antibodies that we generated to acidic
GSLs puriﬁed from P. brasiliensis demonstrated protective
responses in our in vitro and in vivo infection models.
Most signiﬁcantly, the polyclonal antibodies to acidic GSLs
were protective using both the therapeutic and prophylactic
protocols in our murine model of intratracheal P. brasiliensis
infection. The fungal burden was reduced in the lungs of
all groups studied, 15, 30, 45, and 60 days after infection.
The lung sections from the anti-GSL antibody treated groups
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FIGURE 5 | Cytokine levels in the lungs obtained from BALB/c mice that received either 1 mg of polyclonal antibodies against acidic glycolipids or
1 mg anti-BSA polyclonal antibodies (control) 24 h before infection with Pb18 and sacrificed 15 or 30 days post-infection (prophylactic protocol).
∗p < 0.05, #p < 0.05 (student’s t-test).
exhibited well-organized granulomas and less histopathological
damage.
In human PCM, high antibody titers against the major
antigens expressed by the yeast P. brasiliensis correlate with
active disease and the decline in antibody levels is consistent
with a response to antifungal therapy and clinical improvement
(Restrepo et al., 2008). Patients with clinical forms of the disease
usually receive long-term treatment, to allow control of the
clinical manifestations of mycosis and to avoid relapses (Del
Negro et al., 2000; Shikanai-Yasuda et al., 2006).
The eﬀects of six diﬀerent IgG2a and IgG2b were evaluated
in an i.t. infection of P. brasiliensis and the mAbs 19G, 10D
(IgG2a), and 3E (IgG2b) signiﬁcantly reduced lung CFUs. In a
phagocytosis assay using peritoneal and alveolar macrophages
most anti-gp43 mAbs increased signiﬁcantly the phagocytosis
index, with mAb 3E demonstrating the most impressive eﬀect.
The reactivity of mAb 3E was directed to an epitope within
the sequence NHVRIPIGYWAV of gp43 shared with β–1,3-
glucanases of a few other fungal species (Travassos et al., 2007;
Buissa-Filho et al., 2008).
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FIGURE 6 | Cytokine levels in the lungs obtained from BALB/c mice that received either 1 mg of polyclonal antibodies against acidic glycolipids or
1 mg anti- BSA polyclonal antibodies (control) 30 days after infection with Pb18 and sacrificed 45 and 60 days post-infection (therapeutic protocol).
∗p < 0.05, ##p < 0.005 (student’s t-test).
Thomaz et al. (2014) showed that mAbs againstH. capsulatum
hsp60, (4E12 and 7B6, of diﬀerent isotypes), were biologically
active against P. lutzii. Both isotypes enhanced P. lutzii
phagocytosis in vitro. Passive administration of the mAbs prior
to intratracheal infection of P. lutzii in mice signiﬁcantly reduced
the fungal burden in pulmonary tissue.
On testing peritoneal macrophages activated by IFN-γ and
incubated with polyclonal antibodies to acidic GSLs, an enhanced
fungicidal activity of P. brasiliensis yeast forms was observed.
Killing internalized yeasts occurred simultaneous with nitric
oxide production. The involvement of NO in P. brasiliensis killing
is inhibited by IL-10 (Moreira et al., 2010). The eﬀectiveness of
anti-acidic GSL antibodies in vivo reﬂected the three–fourfold
ratio of IFN-γ to IL-10 in the immunized mice. The eﬀect
the nitric oxide in experimental cryptococcosis was also related
to the modulation of cytokine expression, underscoring the
interdependency of cellular and humoral defense mechanisms
(Rivera et al., 2002).
The cytokine proﬁles in both protocols (prophylactic and
therapeutic) showed a mixed activation of Th1 and Th2
cytokines, while similar results were observed previously by
Buissa-Filho et al. (2008), using a protective mAb against gp43
of P. brasiliensis. In our prophylactic protocol, we observed
a trend toward increased levels of IFN-γ and IL-10, whereas
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in the therapeutic protocol IFN-γ IL-4 and IL-12 were
more prominent. The role of IFN-γ mediating activated
macrophages in PCM was previously documented, in which
murine peritoneal macrophages and immortalized cells activated
by IFN-γ displayed enhanced fungicidal activity (reviewed
by Buissa-Filho et al., 2008 and Taborda et al., 2015).
In our present results, polyclonal antibodies against acidic
glycolipids enhance IFN-γ in both protocols; however, the
best results were observed in the therapeutic protocols. As
to the clinical relevance, therapeutic protocols would indeed
be an ideal approach for the administration of antibodies for
combating PCM.
In the present work, polyclonal antibodies directed
to fungal acidic GSLs were shown to exert immune
protection against P. brasiliensis in an intratracheal infection
model.
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